Evaluation of the Efficacy and Safety of Diclofenac HPBCD 25, 50 mg/ml in the Treatment of Post-surgical Pain Following Dental Surgery
Primary Purpose
Dental Pain
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Diclofenac HPBCD
Diclofenac HPBCD
Diclofenac HPBCD
Placebo s.c.
Sponsored by
About this trial
This is an interventional treatment trial for Dental Pain
Eligibility Criteria
Inclusion Criteria:
- Patients undergoing surgical extraction of a single fully or partially impacted mandibular 3rd molar requiring bone removal.
- Patients experiencing moderate to severe post-operative pain within 6 hours from end of surgery.
- Pre-operative laboratory tests in the reference ranges or without clinically significant abnormalities as judged by the Investigator.
Exclusion Criteria:
- Surgery performed under general anaesthesia, or sedation.
- Complications occurring during the surgical procedure or in the period before randomisation as judged by the investigator.
- Acute local or systemic infection at the time of surgery that could confound the post-surgical evaluation.
- Patients with clinical signs of gastritis, gastro-duodenal ulcer, GI bleeding. Other GI disturbances or disease that in the opinion of the investigator could be negatively affected by the administration of NSAIDs.
- Clinical signs or history of coagulation disorders that could be negatively affected by NSAIDs administration.
- Hepatic or renal impairment.
- Patients with significant cardiac impairment, history of cerebrovascular disease, history or peripheral arterial disease, uncontrolled hypertension.
- Hypersensitivity to diclofenac or other NSAIDs or to one of the study medication components.
- Patients under chronic treatment with topical or systemic analgesics/NSAIDs.
- Patients under treatment with any medication that may affect the treatment efficacy evaluation.
- Patients under treatment with any medication whose concomitant use may be susceptible to interactions with diclofenac or may affect safety.
Sites / Locations
- Gabinet Stomatologiczny Bartek
- Centrum Leczenia Chorób Cywilizacyjnych
- Niepubliczny Zakład Opieki Zdrowotnej
- NZOZ Polimedica
- The School of Dentistry; University of Birmingham
- Eastman Dental Institute, University College London
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Active Comparator
Placebo Comparator
Arm Label
Diclofenac HPBCD s.c. 25mg/ml
Diclofenac HPBCD s.c. 50mg/ml
Diclofenac HPBCD s.c. 75mg/ml
Placebo s.c. (1ml)
Arm Description
Outcomes
Primary Outcome Measures
Pain Intensity Difference (PID) on a 0-100 VAS
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
Secondary Outcome Measures
PID
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
PID
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
PID
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
PID
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
PID
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
PID
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
PID
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
PID
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
PID
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
PID
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
PID
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
PID
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
Full Information
NCT ID
NCT00942448
First Posted
July 17, 2009
Last Updated
December 17, 2012
Sponsor
IBSA Institut Biochimique SA
1. Study Identification
Unique Protocol Identification Number
NCT00942448
Brief Title
Evaluation of the Efficacy and Safety of Diclofenac HPBCD 25, 50 mg/ml in the Treatment of Post-surgical Pain Following Dental Surgery
Official Title
Efficacy and Safety Study of Diclofenac HPBCD 25, 50 mg/ml Administered as Single s.c. Dose, in the Treatment of Acute Moderate-to-severe Post-surgical Pain From Dental Surgery (Impacted 3rd Molar Extraction)
Study Type
Interventional
2. Study Status
Record Verification Date
February 2011
Overall Recruitment Status
Completed
Study Start Date
September 2009 (undefined)
Primary Completion Date
January 2010 (Actual)
Study Completion Date
April 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
IBSA Institut Biochimique SA
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The present study is proposed to evaluate the efficacy and safety of single doses of Diclofenac HPBCD subcutaneous (s.c.) (25 mg/1 ml and 50 mg/1 ml) in the treatment of acute moderate-to-severe pain after dental impaction surgery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dental Pain
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
306 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Diclofenac HPBCD s.c. 25mg/ml
Arm Type
Experimental
Arm Title
Diclofenac HPBCD s.c. 50mg/ml
Arm Type
Experimental
Arm Title
Diclofenac HPBCD s.c. 75mg/ml
Arm Type
Active Comparator
Arm Title
Placebo s.c. (1ml)
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Diclofenac HPBCD
Intervention Description
1 single injection at day of dental surgical extraction
Intervention Type
Drug
Intervention Name(s)
Diclofenac HPBCD
Intervention Description
1 single injection at day of dental surgical extraction
Intervention Type
Drug
Intervention Name(s)
Diclofenac HPBCD
Intervention Description
1 single injection at day of dental surgical extraction
Intervention Type
Other
Intervention Name(s)
Placebo s.c.
Intervention Description
1 single injection at day of dental surgical extraction
Primary Outcome Measure Information:
Title
Pain Intensity Difference (PID) on a 0-100 VAS
Description
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
Time Frame
at 1.5 hours after treatment administration
Secondary Outcome Measure Information:
Title
PID
Description
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
Time Frame
at 15 minutes post-dose.
Title
PID
Description
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
Time Frame
at 30 minutes post-dose.
Title
PID
Description
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
Time Frame
at 45 minutes post-dose.
Title
PID
Description
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
Time Frame
at 60 minutes post-dose.
Title
PID
Description
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
Time Frame
at 90 minutes post-dose.
Title
PID
Description
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
Time Frame
at 2 hours post-dose.
Title
PID
Description
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
Time Frame
at 3 hours post-dose.
Title
PID
Description
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
Time Frame
at 4 hours post-dose.
Title
PID
Description
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
Time Frame
at 5 hours post-dose.
Title
PID
Description
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
Time Frame
at 6 hours post-dose.
Title
PID
Description
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
Time Frame
at 7 hours post-dose.
Title
PID
Description
Pain intensity difference (PID) was derived by subtracting each pain intensity score (PI) from the baseline PI score (t0), where PI was assigned by the patient on a 0-100 mm VAS (from 0 = no pain to 100 = worst pain imaginable).
Time Frame
at 8 hours post-dose.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients undergoing surgical extraction of a single fully or partially impacted mandibular 3rd molar requiring bone removal.
Patients experiencing moderate to severe post-operative pain within 6 hours from end of surgery.
Pre-operative laboratory tests in the reference ranges or without clinically significant abnormalities as judged by the Investigator.
Exclusion Criteria:
Surgery performed under general anaesthesia, or sedation.
Complications occurring during the surgical procedure or in the period before randomisation as judged by the investigator.
Acute local or systemic infection at the time of surgery that could confound the post-surgical evaluation.
Patients with clinical signs of gastritis, gastro-duodenal ulcer, GI bleeding. Other GI disturbances or disease that in the opinion of the investigator could be negatively affected by the administration of NSAIDs.
Clinical signs or history of coagulation disorders that could be negatively affected by NSAIDs administration.
Hepatic or renal impairment.
Patients with significant cardiac impairment, history of cerebrovascular disease, history or peripheral arterial disease, uncontrolled hypertension.
Hypersensitivity to diclofenac or other NSAIDs or to one of the study medication components.
Patients under chronic treatment with topical or systemic analgesics/NSAIDs.
Patients under treatment with any medication that may affect the treatment efficacy evaluation.
Patients under treatment with any medication whose concomitant use may be susceptible to interactions with diclofenac or may affect safety.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas Dietrich, Prof
Organizational Affiliation
The school of dentistry, University of Birmingham
Official's Role
Principal Investigator
Facility Information:
Facility Name
Gabinet Stomatologiczny Bartek
City
Kobyłka
ZIP/Postal Code
05-230
Country
Poland
Facility Name
Centrum Leczenia Chorób Cywilizacyjnych
City
Warszawa
ZIP/Postal Code
02-797
Country
Poland
Facility Name
Niepubliczny Zakład Opieki Zdrowotnej
City
Warszawa
ZIP/Postal Code
03-252
Country
Poland
Facility Name
NZOZ Polimedica
City
Zgierz
ZIP/Postal Code
95-100
Country
Poland
Facility Name
The School of Dentistry; University of Birmingham
City
Birmingham
ZIP/Postal Code
B4 6NN
Country
United Kingdom
Facility Name
Eastman Dental Institute, University College London
City
London
ZIP/Postal Code
WC1X8LD
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
Evaluation of the Efficacy and Safety of Diclofenac HPBCD 25, 50 mg/ml in the Treatment of Post-surgical Pain Following Dental Surgery
We'll reach out to this number within 24 hrs